Single positive core prostate cancer in a 12-core transrectal biopsy scheme: Clinicopathological implications compared with multifocal counterpart

Korean Journal of Urology

Volumn 51, Issue 10, 2010, Pages 671-676

  Ahn, Hong Jae ^a   Ko, Young Hwii ^a   Jang, Hoon Ah ^a   Kang, Sung Gu ^a   Kang, Seok Ho ^a   Park, Hong Seok ^a   Lee, Jeong Gu ^a   Kim, Je Jong ^a   Cheon, Jun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Biopsy; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOPSY TECHNIQUE; CANCER GRADING; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; OPERATION DURATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; RISK ASSESSMENT; ROBOTICS; TRANSRECTAL ULTRASONOGRAPHY;

EID: 78149301233     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.10.671     Document Type: Article

References (26)

1. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004;171:1393-401.
2. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992;148:829-32.
3. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score ≤7. Cancer 2000;89:1810-7.
4. Lee AK, Doytchinova T, Chen MH, Renshaw AA, Weinstein M, Richie JP, et al. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core? Urol Oncol 2003;21:123-7.
5. Bulbul MA, El-Hout Y, Haddad M, Tawil A, Houjaij A, Bou Diab N, et al. Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer. Can Urol Assoc J 2007;1:264-6.
6. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162-200.
7. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Actas Urol Esp 2009;33:113-26.
8. O'Connell MJ, Smith CS, Fitzpatrick PE, Keane CO, Fitzpatrick JM, Behan M, et al. Transrectal ultrasound-guided biopsy of the prostate gland: value of 12 versus 6 cores. Abdom Imaging 2004;29:132-6.
9. Patel VR, Thaly R, Shah K. Robotic radical prostatectomy: outcomes of 500 cases. BJU Int 2007;99:1109-12. (Pubitemid 46587913)
10. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-4.
11. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003;169:125-9.
12. Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Ayala AG. Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 1996;105:667-70.
13. Humphrey PA, Vollmer RT. lntraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol 1990;21:799-804.
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
15. Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, et al. Effect of the correction for non-compliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section rotterdam). Int J Cancer 2010;127:2639-44.
16. Klotz LH, Nam RK. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Can J Urol 2006;13(Suppl 1):48-55.
17. Kim SC, Hong JH, Song K, Jeong IG, Song C, Kim CS, et al. Predictive factors for upgrading or upstaging in biopsy Gleason score 6 prostate cancer. Korean J Urol 2009;50:836-42.
18. Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, et al. Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or =12)-core prostate biopsy. World J Urol 2009;27:271-6.
19. Bruce RG, Rankin WR, Cibull ML, Rayens MK, Banks ER, Wood DP Jr. Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Urology 1996;48:75-9.
20. Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, et al. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy - can we predict adverse pathological outcomes? J Urol 2008;180:2436-40.
21. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005;48:895-9.
22. Pepe P, Fraggetta F, Galia A, Candiano G, Grasso G, Aragona F. Is a single focus of low-grade prostate cancer diagnosed on saturation biopsy predictive of clinically insignificant cancer? Urol Int 2010;84:440-4.
23. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 1998;51:759-64.
24. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-8.
25. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000;163:163-6.
26. Gleason DF. Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology 1996;47:289-91.